Robert I Haddad MD

Head & Neck Cancer

Division Chief /Head and Neck Oncology Dana Farber Cancer Institute Professor of Medicine, Harvard Medical School

450 Brookline AvenueDana Farber Cancer InstituteBoston, MA 02215
Phone+1 617-632-3090
Fax+1 617-632-4448

Dr. Haddad is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Haddad's full profile Already have an account?

Education & Training

University of MarylandFellowship, Hematology and Medical Oncology, 1998 - 2001
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 1995 - 1998
St Joseph's University Medical SchoolClass of 1995

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 2001 - 2027
NH State Medical License 2024 - 2024
FL State Medical License 2020 - 2022
ME State Medical License 2020 - 2021
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2012, 2014-2015, 2017
CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2012, 2014-2015, 2017
CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2015, 2017

Clinical Trials

Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)
COMPLETED
PHASE3
Randomized Amifostine For SCCHN
COMPLETED
PHASE2
Title XELOX FOR SALIVARY GLAND CANCERS
TERMINATED
PHASE2

Publications & Presentations

PubMed

Immunotherapy for locally advanced head and neck squamous cell carcinoma: A review.
Robert Haddad, Makoto Tahara, Jean-Pascal Machiels, Theo Borgovan, Arindam Dhar
Cancer Treatment Reviews. 2026-07-11
Clearance of circulating HPV DNA during chemoradiation using a next-generation sequencing liquid biopsy.
Mina Bakhtiar, Yana Al-Inaya, Dipon Das, Danielle N Margalit, Roy B Tishler
Oral Oncology. 2026-07-01
Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in HPV-positive oropharyngeal cancer (ReACT 1.0): an exploratory phase II trial.
Glenn J Hanna, Tulika R Gupta, Lorenzo Trippa, Eleni M Rettig, Danielle N Margalit
Nature Communications. 2026-05-07

Journal Articles

Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma
Glenn J Hanna, Nicole Chau, Robert I Haddad, JAMA Oncology
Genomic Correlates of Response to Immune Checkpoint Blockade in Microsatellite-Stable Solid Tumors
Jeffrey A Engelman, David A Barbie, Nicole G Chau, Glenn J Hanna, Natalie I Vokes, Sabina Signoretti, Pasi A Janne, Robert I Haddad, Lynette M Sholl, Rizwan Haq, Peter..., Nature

Other

Human papillomavirus associated head and neck cancer
Haddad RI
http://www.uptodate.com/contents/human-papillomavirus-associated-head-and-neck-cancer
UpToDate, Wolters Kluwer Health - 2013-04-15

Authored Content

Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Untreated Oral Cavity Squamous Cell CarcinomaAugust 2020

Press Mentions

FDA Approves Immune Checkpoint Inhibitor Drug for Patients with Resectable Locally Advanced Head and Neck Cancer, Backed by Dana-Farber ResearchJune 13th, 2025
Immunotherapy Before and After Surgery Boost Longer Event-Free Survival in Head and Neck CancerMay 5th, 2025
HMN 2025: How Immunotherapy Earlier Than and After Surgical Procedure Improves Outcomes in Head and Neck Cancer, Medical Trial RevealsApril 29th, 2025